

Analysis of the Posttranslational Modifications of the Influenza Virus M₂ Protein

LESLIE J. HOLSINGER,^{1†} MARGARET A. SHAUGHNESSY,² AURELIA MICKO,³
LAWRENCE H. PINTO,³ AND ROBERT A. LAMB^{1,2*}

*Department of Biochemistry, Molecular Biology and Cell Biology,¹ Howard Hughes Medical Institute,²
and Department of Neurobiology and Physiology,³ Northwestern University, Evanston, Illinois 60208-3500*

Received 1 September 1994/Accepted 4 November 1994

The sites of posttranslational modifications of the influenza A virus M₂ protein were examined, and the effect of these modifications on the M₂ protein ion channel activity was analyzed. Cysteine residues 17 and 19 in the M₂ protein ectodomain form disulfide bonds. The cytoplasmic tail is posttranslationally modified by palmitoylation, and mutagenic studies support the view that cysteine residue 50 is the site for fatty acylation. In addition, the cytoplasmic tail of the M₂ protein was found to be posttranslationally modified by the addition of phosphate to specific serine residues. Site-directed mutagenesis of serine residues in the M₂ protein cytoplasmic tail, combined with phosphoamino acid analysis, indicated that serine residue 64 is the predominant site for phosphorylation but that serine residues 82, 89, and 93 were also phosphorylated but to much lesser extents. Disulfide-bond formation, palmitoylation, and phosphorylation occurred on M₂ protein expressed in mammalian cells infected with influenza virus, in mammalian cells in which the M₂ protein was expressed from DNA expression vectors, and when the M₂ protein was expressed in oocytes of *Xenopus laevis*. The membrane currents of oocytes of *Xenopus laevis* expressing wild-type and site-specifically altered forms of the M₂ protein, to ablate posttranslational modifications, indicated that none of the posttranslational modifications significantly affected the ion channel activity of the M₂ protein in oocytes. Therefore, these data do not indicate a functional role for posttranslational modifications of the M₂ protein in its ion channel activity.

The influenza A virus M₂ protein, which is encoded by a spliced mRNA derived from RNA segment 7, is a small integral membrane protein (97 amino acids) that is expressed at the plasma membrane of virus-infected cells and is oriented such that it has 23 N-terminal extracellular residues, a transmembrane domain of 19 residues, and a 54-residue cytoplasmic tail (20, 24, 26, 46). The M₂ protein forms a homotetramer composed of a pair of disulfide-linked dimers or a disulfide-linked tetramer (11, 28, 40, 45). Although the M₂ protein is abundantly expressed at the plasma membrane of virus-infected cells, it is a minor component of the virion envelope in comparison with the abundant hemagglutinin and neuraminidase (13, 15, 26, 46).

The M₂ protein transmembrane domain was deduced to be the target of the anti-influenza virus drug amantadine, as drug-resistant mutants contained amino acid changes in the M₂ protein transmembrane domain (8). From studies on the effect of amantadine on virus replication, it was proposed that the M₂ protein functions as an ion channel that permits ions to enter endocytosed virions and to function as a modulator of pH in intracellular compartments (7, 22, 38, 40).

Direct evidence that the M₂ protein has ion channel activity was obtained by expressing the M₂ protein in oocytes of *Xenopus laevis*. It was found that in response to hyperpolarizing membrane voltages, an inward whole-cell current that is blocked by amantadine and activated by the low pH found in endosomes could be recorded (35). More recently, it has been

demonstrated that the M₂ protein forms an ion channel in mammalian cells by recording amantadine-sensitive currents that were activated by low pH from CV-1 cells expressing the M₂ protein (43). The ion selectivity and amantadine sensitivity of the M₂ ion channel is determined by the amino acid sequence of the transmembrane domain which forms the pore of the channel (12, 35, 43). The notion that the transmembrane domain of the M₂ protein forms a pore was reinforced by finding that a 25-residue peptide corresponding to this domain inserts into planar lipid bilayers and promotes the formation of channels (at pH 1 to 2) which fail to open upon addition of amantadine (3). In addition, when purified M₂ protein was incorporated into planar lipid bilayers, ionic conductances that were blocked by amantadine and activated by lowered pH were observed (41).

The M₂ protein is posttranslationally modified by the formation of intermolecular disulfide bonds at cysteine residues 17 and 19 (11). The M₂ protein is also posttranslationally modified by palmitoylation through a thioether linkage (39, 42). In addition to acylation, the M₂ protein is posttranslationally modified by phosphorylation (40, 44). However, data to demonstrate the site of phosphorylation have not been reported.

We describe here properties of altered M₂ molecules to examine the effect of disulfide bond formation and palmitoylation on the M₂ protein ion channel activity. In addition, we have determined the sites of phosphorylation at specific serine residues in the cytoplasmic tail and determined the effect of phosphorylation on the ion channel activity of the M₂ protein.

MATERIALS AND METHODS

Site-specific mutagenesis and construction of recombinant plasmids. The cDNA to the influenza virus A/Udorn/72 M₂ mRNA (14, 46) was cloned into the *Bam*HI site of pGEM3Zf(+) and used as a template for phagemid-based mutagenesis (32). The M₂ cDNA was also cloned into the *Bam*HI site of pGEM3 for

* Corresponding author. Mailing address: Howard Hughes Medical Institute, Department of Biochemistry, Molecular Biology and Cell Biology, Northwestern University, 2153 N. Campus Dr., Evanston, IL 60208-3500. Phone: (708) 491-5433. Fax: (708) 491-2467. Electronic mail address: ralamb@nwu.edu

† Present address: Howard Hughes Medical Institute, Stanford University Medical Center, Stanford, CA 94305-5428.

site-directed mutagenesis by the unique-site elimination system (2) performed by the unique-site elimination mutagenesis procedure of Pharmacia-LKB, Inc., Piscataway, N.J. The nucleotide sequences of the altered cDNAs in both the pGEM3Zf(+) phagemid vector and the pGEM3 vector were confirmed by dideoxynucleotide chain-terminating sequencing (36).

Mammalian cell expression of M₂ proteins. The cysteine-altered M₂ cDNAs were expressed in CV-1 cells by using the simian virus 40 (SV40) VP1 replacement vector pSV73E/K (46) such that the M₂ cDNA was under the control of the SV40 late-region promoter, splicing, and polyadenylation signals. SV40-M₂ recombinant virus stocks were produced as described previously (11, 23). The serine-altered M₂ cDNAs were expressed in HeLa T4 cells by a modification of the vaccinia virus-T7 RNA polymerase system (vac-T7) of Fuerst et al. (6) as described previously (30). Only cDNAs cloned in pGEM3 were used, because it was found that the pGEM3 vector yields approximately 50-fold-higher expression levels of protein than does pGEM3Zf(+) for the same cloned M₂ cDNA.

Microinjection and culture of oocytes. Ovarian lobules from *Xenopus laevis* females (Nasco, Fort Atkinson, Wis.) were surgically removed and treated with collagenase B (2 mg/ml; Boehringer Mannheim Biochemicals, Indianapolis, Ind.) (35). Selected oocytes (stages V and VI) were given injections of 50 nl of RNA (1.0 µg/µl) via a 20-µm-diameter glass pipette, and the oocytes were maintained in ND96 (35) at 17°C.

Metabolic labeling of mammalian cells. CV-1 cells were grown in 10% fetal calf serum in Dulbecco's modified Eagle's medium (DMEM) at 37°C in 5% CO₂, infected with recombinant SV40, and labeled 45 to 48 h postinfection (p.i.) with [³⁵S]cysteine (100 µCi/ml) in DMEM lacking cysteine (DMEM Cys⁻) as described previously (11, 21, 26). Recombinant SV40-infected cells were labeled 45 to 48 h p.i. with [³H]palmitic acid (300 µCi/ml; 80 Ci/mmol; New England Nuclear Research Products, Boston, Mass.) in DMEM supplemented with 5 mM sodium pyruvate or were labeled 45 to 48 h p.i. with ³²P_i (500 µCi/ml; ICN Radiochemicals, Costa Mesa, Calif.) in phosphate-free DMEM. HeLa T4 cells expressing serine-altered proteins, obtained by the vac-T7 expression system at 4 h posttransfection, were incubated for 30 min in DMEM Cys⁻ and labeled for 1 h with [³⁵S]cysteine (100 µCi/ml) in DMEM Cys⁻. HeLa T4 cells expressing the serine-altered M₂ proteins were labeled with phosphate by being incubated at 4 h posttransfection in phosphate-free DMEM for 1 h and then labeled for 2 h with ³²P_i (500 µCi/ml) in phosphate-free DMEM. For control experiments, CV-1 cells were infected with influenza virus A/Udorn/72 or Sendai virus as described previously (18, 25) and at 6 or 14 h p.i., respectively, were incubated in phosphate-free DMEM for 1 h. They were then labeled for 2 h with ³²P_i (500 µCi/ml) in phosphate-free DMEM.

Metabolic labeling of oocytes. Oocytes were incubated from 24 to 48 h postinjection with ND96 supplemented with either [³⁵S]methionine (250 µCi/ml) or ³²P_i (20 mCi/ml).

Microsome preparation and proteolysis. SV40 wild-type (wt) M₂ recombinant virus-infected cells were labeled from 45 to 48 h p.i. with [³⁵S]cysteine in DMEM Cys⁻ or with ³²P_i in phosphate-free DMEM before the preparation of crude microsomal membranes (31, 46). Microsomes were treated with *N*-tosyl-L-phenylalanine chloromethyl ketone-treated trypsin (200 µg/ml; Worthington Biochemical Corp., Freehold, N.J.) and isolated by centrifugation on a sucrose cushion essentially as described previously (29).

Immunoprecipitation and SDS-PAGE. Labeled oocytes were homogenized in, per oocyte, 75 µl of radioimmunoprecipitation assay (RIPA) buffer containing 50 mM iodoacetamide and a cocktail of protease inhibitors as described previously (33). Mammalian cells were lysed in RIPA buffer. Extracts were immunoprecipitated (21) with M₂-specific 14C2 monoclonal antibody (MAB) ascitic fluid (45). For polypeptides labeled with ³²P_i, 1 µg of RNase A per ml was added to the lysate prior to addition of 14C2. Samples were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 17.5% polyacrylamide-4 M urea gels and processed for fluorography or autoradiography as described previously (18, 33).

Electrophysiological recordings were made on injected oocytes, and the oocytes were saved for immunoblotting. Individual unlabeled oocytes were lysed in 100 µl of RIPA buffer and extracted once with 1,1,2-trichlorotrifluoroethane to remove yolk and pigment proteins. From 5 to 10 µl of lysates was analyzed on 17.5% polyacrylamide-4 M urea gels and electrotransferred to polyvinylidene difluoride membranes (Millipore, Bedford, Mass.) with a Trans-Blot Semidry transfer cell (Bio-Rad, Richmond, Calif.). Immunoblotting with a 1:3,000 dilution of M₂-specific 14C2 ascitic fluid (45) and the ECL system (Amersham International, Arlington Heights, Ill.) was done as described previously (12). Autoradiography was performed with preflashed X-ray film (27) and quantified by laser-scanning densitometry on an LKB Ultrascan XL Densitometer (Pharmacia-LKB, Piscataway, N.J.). For quantification of blots, 50 to 400 pg of purified M₂ protein, the precise amount depending on the M₂ mutant under analysis, was run with all samples to generate a standard curve. M₂ protein was purified from detergent lysates of influenza A/Udorn/72-infected CV-1 cells by immunoadfinity chromatography with M₂-specific purified 14C2 immunoglobulin G coupled to CNBr-activated Sepharose 4B as described previously (11).

Phosphoamino acid analysis. The method for phosphoamino acid analysis was adapted from that described previously (17, 19). M₂ protein was immunoprecipitated and the polypeptide was separated on 17.5%-4 M urea gels under reducing conditions, and phosphate-labeled M₂ polypeptides were excised from dried gels with the autoradiogram as a template. Peptides were eluted from the

gel pieces by incubation in 50 mM NH₄HCO₃-0.1% SDS, incubated with agitation overnight at 37°C, and filtered through glass wool. Peptides were precipitated with 10% trichloroacetic acid, with 20 µg of gamma globulin as the carrier, and lyophilized. Peptides were hydrolyzed in 6 N HCl for 3 h at 110°C and analyzed on 20-by-20-cm cellulose thin-layer plates (100 µM; Brinkman, Westbury, N.Y.) by two-dimensional electrophoresis. In the first dimension, the buffer was formic acid-glacial acetic acid-H₂O (pH 1.9) (50:156:1,794) and electrophoresis was carried out at 1,000 V for 60 min. In the second dimension, the buffer was glacial acetic acid-pyridine-H₂O (pH 3.5) (100:10:1,890) and electrophoresis was carried out at 1,000 V for 75 min essentially as described previously (1). Phosphoserine, phosphothreonine, and phosphotyrosine were used as standards (Sigma Chemical Co., St. Louis, Mo.) and identified by staining with 0.2% ninhydrin dissolved in acetone.

Electrophysiological recordings. Whole-cell currents were recorded from oocytes with a two-electrode voltage clamp apparatus 48 to 72 h after mRNA injection (35). For all measurements described herein, the small endogenous current exhibited by control oocytes injected with antisense RNA was subtracted from the measured current to yield the current reported.

RESULTS AND DISCUSSION

Expression of M₂ cysteine-altered mutants in oocytes of *X. laevis*. The role of M₂ cysteine residues in M₂ protein disulfide bond formation and their role in forming oligomers were examined previously (11) by converting each of the two extracellular cysteine residues and the single cytoplasmic cysteine residue to serine residues (C-1 [C17S], C-2 [C19S], and C-3 [C50S]) and expressing the altered M₂ proteins in eukaryotic cells. It was found that removal of either one of the N-terminal cysteines at residue 17 or 19 resulted in the formation of tetramers that consisted of a pair of noncovalently associated disulfide-linked dimers, indicating that each of the extracellular cysteine residues is equally competent for forming disulfide bonds. When both cysteine residues were removed from the M₂ N-terminal domain, no disulfide-linked forms were observed, but chemical cross-linking data of this double-cysteine mutant (C-1,2 [C17S, C19S]) in membranes indicated that the molecule was still a tetramer (11). It has also been shown previously that the M₂ protein is modified by covalent attachment of palmitate (39, 42). The palmitate associated with M₂ is susceptible to removal by hydroxylamine (39, 42) and by boiling the M₂ protein in 5% mercaptoethanol (42), treatments which are indicative of a thioether linkage. Palmitoylation occurs on the cytoplasmic tails of integral membrane proteins (37), and because there is only a single cysteine (residue 50) in the M₂ cytoplasmic tail, it is presumed this is the site of palmitoylation. In addition, the replacement of cysteine 50 with phenylalanine in some influenza viruses, e.g., A/equine/Fontainebleau/79 (H3N8), results in a concomitant loss of palmitate labeling, a finding which points to cysteine 50 as the site of palmitate attachment (39).

To determine the effect of the cysteine alterations on the M₂ protein ion channel activity, synthetic mRNAs were injected into oocytes of *X. laevis*. Synthesis of the M₂ protein mutants was examined by metabolically labeling oocytes with [³⁵S]cysteine for 24 h. M₂ proteins were immunoprecipitated, and polypeptides were analyzed by SDS-PAGE under nonreducing conditions. As shown in Fig. 1, a pattern of polypeptide species consistent with those observed previously in mammalian cells (11) was found. The wt and C-3 M₂ proteins were found to form a mixture of disulfide-linked dimers (~30 kDa) and disulfide-linked tetramers (~60 kDa), whereas mutants C-1 and C-2 were found to form disulfide-linked dimers. The replacement of both cysteine residues in the extracellular domain of M₂ (C-1,2) eliminated the formation of disulfide bonds, and the protein migrated as a 15-kDa form similar in mobility to that observed under reducing conditions. The accumulation of the C-1,2 mutant was reduced in comparison with the other cysteine-altered M₂ proteins. It is possible that the accumula-




FIG. 1. Expression of the M₂ protein cysteine mutants in oocytes of *X. laevis*. (A) Schematic diagram of cysteine mutants which were constructed previously (11). The M₂ protein transmembrane domain is represented by a solid box. (Mutant C-1, C17S; mutant C-2, C19S; mutant C-3, C50S; mutant C-1,2, C17S,C19S). (B) Synthetic mRNAs were transcribed from either pGEM3 or pGEM3Zf(+) encoding the wt M₂ and cysteine-altered M₂ proteins and were microinjected (50 nl of 1- μ g/ μ l RNA) into oocytes of *X. laevis*. At 24 h postinjection, oocytes were labeled with [³⁵S]methionine for 16 h and homogenized and detergent lysates were prepared in the presence of 50 mM iodoacetamide. Proteins were immunoprecipitated with an M₂-specific MAb (14C2) and analyzed by SDS-PAGE under nonreducing conditions. Positions of the M₂ monomer, dimer, and tetramer bands (15, 30, and 60 kDa, respectively) are shown on the right.

tion of the C-1,2 mutant is reduced because it is less stable than its disulfide-bonded counterparts, but this possibility has not been explored.

To provide evidence that cysteine residue 50 is the site of palmitate addition, an attempt was made to label oocytes expressing wt M₂ and M₂ mutant C-3 with [³H]palmitic acid. However, when 2 mCi of [³H]palmitic acid per ml was used, it was not possible to detect labeling on wt M₂ even after a 2-month autoradiographic exposure. Presumably, the fatty acid pool size in oocytes is too large to obtain detectable radioisotopic incorporation. Indirect evidence that M₂ protein synthesized in *X. laevis* oocytes is modified by addition of palmitate was obtained by boiling the immunoprecipitated M₂ protein in 5% dithiothreitol and observing a slight shift in mobility (data not shown), as described previously (42). However, when wt M₂ and the M₂ C-3 mutant were expressed in CV-1 cells with SV40-M₂ recombinant virus vectors, wt M₂ could be labeled with [³H]palmitic acid whereas the M₂ C-3 mutant protein could not (Fig. 2). Thus, these data provide further evidence to suggest that M₂ cysteine residue 50 is the site of palmitate addition.

Ion channel activity of the M₂ cysteine-altered mutants. To examine for the ion channel activity of the cysteine-altered M₂




FIG. 2. Lack of addition of palmitate for M₂ mutant C-3. SV40-M₂ recombinant-infected CV-1 cells were labeled with [³⁵S]cysteine ([³⁵S]cys) or [³H]palmitic acid ([³H]palm) from 45 to 48 h p.i. Detergent lysates were prepared in the presence of 50 mM iodoacetamide, immunoprecipitated with 14C2 M₂-specific ascitic fluid, and analyzed by SDS-PAGE under reducing conditions. Only the relevant portion of the autoradiograph is shown.

proteins expressed in oocytes of *X. laevis*, a two-electrode voltage clamp procedure was used and total membrane currents were measured. The currents were studied by holding the membrane voltage at -40 mV and hyperpolarizing the membrane with step voltage clamp pulses from -130 to -60 mV in normal Barth's solution (pH 7.5) and in Barth's solution (pH 6.2). The peak amplitudes of the whole-cell currents measured following hyperpolarization at -130 mV were normalized to the amount of accumulated M₂ protein (determined by a quantitative immunoblot procedure) in individual oocytes, and the current (microamps) at pH 6.2 per nanogram of M₂ protein accumulated was measured. The current, protein, and their ratio varied from batch to batch. Within a single batch, the ratio was found to be spread only over a twofold range for the wt M₂ protein and the cysteine-altered mutants (0.124 to 0.273 \pm 0.024 μ A/ng [mean \pm standard error of the mean, n = 6]). Following activation at pH 6.2, the currents of the wt M₂ and all the cysteine-altered M₂ proteins were blocked by the M₂ channel blocker amantadine (data not shown). When the pH sensitivities of the membrane currents of oocytes expressing the wt M₂ and cysteine-altered M₂ proteins were compared




FIG. 3. Modulation of the membrane current of oocytes expressing the wt and cysteine-altered M₂ proteins by pH. Oocytes were given microinjections of synthetic RNA transcripts encoding the wt M₂ and cysteine-altered M₂ proteins. Electrophysiological measurements were performed at 48 to 72 h p.i. The peak amplitude of the amantadine-sensitive inward currents following a hyperpolarization pulse of -130 mV for the indicated M₂ protein is plotted against extracellular pH. Background endogenous currents recorded from oocytes given injections of antisense RNA were subtracted from each datum point. For each datum point, n = 5. Symbols: □, wt; ●, C-1; ○, C-2; ▲, C-3; ■, C-1,2.

over the pH range from 7.5 to 5.4, it was found that all the mutants had similar slopes of pH activation (Fig. 3).

The observation that disulfide bond formation is not essential for ion channel activity was not unexpected, because oligomerization of the M_2 protein occurs in the absence of cysteine residues 17 and 19 (11). It is possible that oligomerization is specified largely by the transmembrane domain, because deletions in this domain can alter the form of the M_2 oligomer (12). The lack of a significant change in the pH activation curve of the ion channel activity of M_2 cysteine-altered mutant C-1,2 from wt M_2 protein suggests that the presumptive conformation change in the M_2 protein on pH activation does not depend on disulfide bond formation. Although modification of the cysteine residues in the M_2 protein by disulfide bond formation or fatty acylation appears to have no role in significantly modulating M_2 protein ion channel activity, these modifications may play other roles in the life cycle of influenza virus, such as stabilizing the M_2 protein in the membrane during virus budding or facilitating the incorporation of M_2 protein in the virion particle.

Nature of the influenza virus M_2 protein phosphorylated residue. It has been shown previously that when influenza virus-infected cells are metabolically labeled with ^{32}P , the M_2 protein is phosphorylated (40, 44). To identify the phosphorylated amino acid residue, influenza virus-infected cells were metabolically labeled with ^{32}P , the M_2 protein was immunoprecipitated and analyzed by SDS-PAGE, and the M_2 protein band was excised and hydrolyzed with 6 N HCl. Amino acids were separated by two-dimensional high-voltage electrophoresis. As shown in Fig. 4, the phosphorylated residue was found to be phosphoserine. To rule out the possibility that phosphothreonine was hydrolyzed to threonine by the procedure used, metabolically ^{32}P -labeled M protein of Sendai virus, which is known to contain phosphothreonine (19), was hydrolyzed, and phosphothreonine was recovered (Fig. 4). For mutagenesis experiments (see below), it was necessary to express the M_2 protein with eukaryotic vectors. To eliminate the possibility that the protein kinase activities present in an influenza virus-infected cell phosphorylate M_2 protein differently from vector-expressing cells, the phosphoamino acid(s) of M_2 protein expressed by the vac-T7 expression system as well as recombinant SV40 expression was investigated and found to be phosphoserine in all cases (Fig. 4). Therefore, the nature of the M_2 protein phosphorylated residues is not changed between influenza virus-infected and vector-expressing cells.

Identification of the M_2 protein-phosphorylated serine residues. The N-terminal domain of the M_2 protein expressed at the cell surface is accessible to protease digestion, and the C-terminal cytoplasmic domain of the M_2 protein in a preparation of crude microsomes is accessible to protease digestion (26, 46). To determine the domain of the M_2 protein modified by phosphorylation, ^{32}P -labeled M_2 protein expressed at the cell surface, ^{32}P -labeled M_2 protein contained in microsomes, and [^{35}S]cysteine-labeled M_2 protein contained in microsomes were digested with protease and the proteolytic fragments were immunoprecipitated with N-terminal domain-specific MAb 14C2 or C-terminal domain-specific MAb 1D6-tail. The protease-trimmed cell surface M_2 protein, which lacks the N-terminal domain, was labeled with ^{32}P (Fig. 5A). In comparison, the ~7-kDa trypsin-resistant microsomal M_2 fragment that lacks the M_2 cytoplasmic tail could not be identified when the M_2 protein was ^{32}P -labeled (Fig. 5A), but this fragment could be readily identified when the M_2 protein in microsomes was labeled with [^{35}S]cysteine (Fig. 5B). These data indicate that the M_2 protein cytoplasmic tail is the region modified by phosphorylation.




FIG. 4. Phosphoamino acid analysis of wt and serine-altered M_2 proteins. The M_2 protein was expressed in influenza virus A/Udorn/72-infected CV-1 cells and SV40- M_2 recombinant-infected CV-1 cells and from cDNA by the vac-T7 expression system. In addition, a serine-altered M_2 protein, M_2 -S64A,S71A was expressed by the vac-T7 expression system. The M_2 proteins were metabolically labeled with ^{32}P . They were immunoprecipitated with 14C2 MAb and analyzed by SDS-PAGE. Gel bands were excised from dried gels with the autoradiograph as a guide. Polypeptides from ^{32}P -labeled Sendai virus-infected CV-1 cells were analyzed directly by SDS-PAGE, and the Sendai virus M protein band was excised from the dried gel. Hydrolysis of polypeptides to amino acids with 6 N HCl and analysis of phosphoaminoacids by two-dimensional high-voltage electrophoresis on cellulose plates were done as described in Materials and Methods. The mobilities of coelectrophoresed phosphoserine (area 1), phosphothreonine (area 2), and phosphotyrosine (area 3) standards were identified by staining with ninhydrin, and their positions were marked. ^{32}P -labeled amino acids were detected by autoradiography. For the purpose of comparison, panel vacT7 M_2 -Ser_{64,71}A was exposed for autoradiography ~seven times longer than was panel vacT7 M_2 .

Each of the five M_2 cytoplasmic tail serine residues (Fig. 6D) is in a sequence context such that it could be phosphorylated by a known cellular protein kinase (Table 1). To identify the phosphorylated residue in the M_2 cytoplasmic tail, the five serine residues were individually changed to alanine and then combinations of serine-to-alanine changes were made as necessary. To simplify the number of altered M_2 proteins that had to be constructed initially, a translational stop codon at residue 89 (S-89_{STOP}) was introduced to eliminate serine residues 89 and 93. The serine-altered M_2 molecules were expressed in HeLa T4 cells by using the vac-T7 expression system and were metabolically labeled with ^{32}P or [^{35}S]cysteine. As shown in Fig. 6, the mutation S64A resulted in a ~85% reduction in phosphate labeling of M_2 protein compared with wt M_2 protein, and thus serine 64 is the predominant site for phosphate addition. However, the molar ratio of phosphate addition on M_2 residue serine 64 to unphosphorylated serine is not known. Serine 64 is within the recognition motif for both calmodulin-dependent protein kinase II and S6 kinase II (Table 1). To ensure that the residual phosphorylation found on M_2 -S64A protein occurred on a serine residue and that the mutation had not caused a change to threonine or tyrosine, the phosphoamino acid content of S64A,S71A was determined. The residual phosphorylation was found to remain on the serine residue (Fig. 4, panel S_{64,71}A). To investigate which other serine residue was phosphorylated in addition to serine 64 several serine mutants were examined for phosphorylation (S64A,S71A, S64A,S71A,S82A, S64A,S71A,S82A,S89A, S89A, S82A,S89A, S64A,S71A,S82A,S89A, S64A,S71A,S82A, S89_{STOP}, S93A). Examples of expression of some of these





FIG. 5. Localization of the M₂ phosphorylation site. SV40-M₂ recombinant-infected CV-1 cells at 45 to 48 h p.i. were labeled with [³⁵S]cysteine or ³²P_i as described in Materials and Methods. Where indicated, cell surfaces were treated with (+) or without (-) trypsin to trim the N-terminal domain of M₂, as described previously (26). Microsomes were prepared and treated with (+) or without (-) trypsin as described previously (46). Polypeptides were immunoprecipitated with the M₂ N-terminal domain-specific MAb 14C2 or with an M₂ C-terminal domain-specific MAb 1D6-tail. The position of the M₂ protease-protected microsome fragment, consisting of the N-terminal and transmembrane domains of M₂, is indicated by the arrowheads. The stars indicate the cell surface protease-trimmed M₂ that lacks the N-terminal domain. The M₂ 1D6-tail specific mouse hybridoma was made as described previously (10). The specificity of 1D6-tail for the M₂ cytoplasmic tail is demonstrated in this figure. 1D6-tail is reactive with cell surface protease-trimmed M₂ (in contrast to the lack of reactivity of 14C2), but it is not reactive with the proteolytic fragment of M₂ remaining after protease treatment of microsomes. The remaining ~7-kDa fragment of M₂ consists of the M₂ N-terminal ectodomain and the transmembrane domain. In contrast to the reactivity of 1D6-tail, MAb 14C2 does recognize this fragment.

serine-altered M₂ proteins are shown in Fig. 6. Our data indicate that serine 71 is not modified by addition of phosphate, because the level of phosphate labeling of mutant S64A,S71A is the same as for the single mutant S64A at a comparable level



D.

Met-Ser-Leu-Leu-Thr-Glu-Val-Glu-Thr-Pro-Ile-Arg-Asn-Glu-Trp-Gly- (16)
 Cys-Arg-Cys-Asn-Asp-Ser-Ser-Asp-Pro-Leu-Val-Val-Ala-Ala-Ser-Ile- (32)
Ile-Gly-Ile-Leu-His-Leu-Ile-Leu-Trp-Ile-Leu-Asp-Arg-Leu-Phe-Phe- (48)
 Lys-Cys-Ile-Tyr-Arg-Phe-Phe-Glu-His-Gly-Leu-Lys-Arg-Gly-Pro-Ser-⁶⁴ (64)
 Thr-Glu-Gly-Val-Pro-Glu-Ser⁷¹-Met-Arg-Glu-Glu-Tyr-Arg-Lys-Glu-Gln- (80)
 Gln-Ser⁸²-Ala-Val-Asp-Ala-Asp-Asp-Ser⁸⁹-His-Phe-Val-Ser⁹³-Ile-Glu-Leu- (96)
 Glu- (97)

FIG. 6. Phosphorylation of serine-altered M₂ proteins. The serine-altered M₂ mutants, S64A,S71A,S82A, and S89_{STOP} (serine residue 89 changed to a translation stop codon, TGA) were constructed as described in Materials and Methods. (A and B) The M₂ proteins were expressed in HeLa T4 cells by the vac-T7 expression system and cells labeled with [³⁵S]cysteine (A) or ³²P_i (B). (C) Synthetic mRNAs were transcribed from either pGEM3 or pGEM3Zi(+) and microinjected (50 nl of 1-μg/μl RNA) into oocytes of *X. laevis*. At 24 h postinjection, oocytes were labeled with ³²P_i for 24 h and homogenized, and detergent lysates were prepared in the presence of 50 mM iodoacetamide. Proteins were immunoprecipitated with the M₂-specific 14C2 MAb and analyzed by SDS-PAGE under reducing conditions. Only the relevant portion of the autoradiograph is shown. (D) Amino acid sequence of the M₂ protein, showing the five serine residues in the cytoplasmic tail. The M₂ transmembrane domain is boxed.

of [³⁵S]methionine-labeled M₂ protein (data not shown). However, serine residues 82, 89, and 93 are all phosphorylated to minor extents (Fig. 6). Because it is possible that phosphorylation of the residues that are modified to minor extents become moving targets in the serine-altered mutants, the minor phosphorylated residues were not investigated further. Before ion channel activities of the serine-altered M₂ proteins were measured, the phosphorylation pattern of the proteins in *X. laevis* oocytes was investigated. As anticipated, a very similar pattern of phosphorylation (examples shown in Fig. 6C) to that observed in mammalian cells was found, with M₂ residue serine 64 being the predominant phosphorylated residue.

Ion channel activity of the M₂ serine-altered mutants. It was of interest to determine a possible effect of phosphorylation of the M₂ protein on its ion channel activity, as phosphorylation has been shown to be both a positive and negative regulator of the function of other ion channels (reviewed in reference 9). In addition, the predominant phosphoamino acid, serine 64, is conserved in the M₂ protein of all influenza virus subtypes. The ion channel activities of the serine-altered M₂ proteins S64A, S64A,S71A,S82A, and S64A,S93A were examined by expressing the proteins in oocytes of *X. laevis* and measuring total membrane currents by a two-electrode voltage clamp procedure as described above. The current, the protein, and their

TABLE 1. Protein kinase phosphorylation site motifs in the influenza virus M₂ protein

M ₂ residue	M ₂ Ser within recognition motif ^a	Protein kinase	Reference
Ser-64	XRXXS*X	Calmodulin-dependent protein kinase II S6 kinase II	34 4
Ser-71	XS*XXEX	Casein kinase II	16
Ser-82	XEXXS*X	Casein kinase I	16
Ser-89	XS*XXXS(P)X	Glycogen synthase kinase-3	5
Ser-93	XS*XEX	Mammary gland casein kinase	16

^a *, phosphorylated residue.

ratio varied from batch to batch of oocytes. Within a single batch, the ratio was found to be spread only over a 1.7-fold range for the wt M₂ protein and for each of the three serine-altered mutants (0.41 ± 0.3 to 0.69 ± 0.4 μ A/ng [mean \pm SEM, $n = 6$ for each]), which suggests that the M₂ protein ion channel activity is not affected by phosphorylation.

Summary. The influenza virus M₂ ion channel is one of the smallest regulatable ion channels known to date, and it may be amenable to structural studies. To understand the mechanism of action of the M₂ ion channel, it is necessary to examine the effects of known posttranslational modifications on its activity. The influenza virus M₂ protein is posttranslationally modified by the formation of disulfide bonds with cysteine residues 17 and 19. The cytoplasmic tail is posttranslationally modified by palmitoylation, and all the available data indicate that cysteine residue 50 is the site for the thio-ether linkage of the fatty acid. The M₂ protein is also posttranslationally modified by the addition of phosphate to the cytoplasmic tail on serine residues. The predominant (~85%) phosphoserine residue is serine 64, but serine residues 82, 89, and 93 are also phosphorylated to minor extents. The posttranslational modifications occur on M₂ protein expressed in mammalian cells infected with influenza virus, when M₂ protein is expressed in mammalian cells by using expression vectors, and on M₂ protein expressed in oocytes of *X. laevis*. However, none of the posttranslational modifications dramatically affect the ion channel activity of the M₂ protein expressed in oocytes of *X. laevis*. Therefore, if there is a role for the posttranslational modifications of the M₂ protein described here in the life cycle of the virus, it would most probably be in the formation of infectious influenza virus virions, and this remains to be determined.

ACKNOWLEDGMENTS

This research was supported by Public Health Service research grants AI-20201 (R.A.L.) and AI-31882 (L.H.P.) from the National Institute of Allergy and Infectious Diseases. R.A.L. is an Investigator of the Howard Hughes Medical Institute (HHMI). A.M. performed some of the electrophysiological work as a C98 independent studies project at Northwestern University and continued as an HHMI-supported undergraduate summer student.

REFERENCES

- Boyle, W. J., P. van der Geer, and T. Hunter. 1991. Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. *Methods Enzymol.* **201**:110–148.
- Deng, W. P., and J. A. Nickoloff. 1992. Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. *Anal. Biochem.* **200**:81–88.
- Duff, K. C., and R. H. Ashley. 1992. The transmembrane domain of influenza A M₂ protein forms amantadine-sensitive proton channels in planar lipid bilayers. *Virology* **190**:485–489.
- Erikson, E., and J. L. Maller. 1988. Substrate specificity of ribosomal S6 kinase II from *Xenopus* eggs. *Second Messengers Phosphoproteins.* **12**:135–143.
- Fiol, C. J., A. M. Mahrenholz, Y. Wang, R. W. Roeske, and R. J. Roach. 1987. Formation of protein kinase recognition sites by covalent modification of the substrate. *J. Biol. Chem.* **262**:14042–14048.
- Fuerst, T. R., E. G. Niles, F. W. Studier, and B. Moss. 1986. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T₇ RNA polymerase. *Proc. Natl. Acad. Sci. USA* **83**:8122–8126.
- Hay, A. J. 1992. The action of adamantanes against influenza A viruses: inhibition of the M₂ ion channel protein. *Semin. Virol.* **3**:21–30.
- Hay, A. J., A. J. Wolstenholme, J. J. Skehel, and M. H. Smith. 1985. The molecular basis of the specific anti-influenza action of amantadine. *EMBO J.* **4**:3021–3024.
- Hille, B. 1992. *Ionic channels of excitable membranes.* Sinauer Associates Inc., Sunderland, Mass.
- Holsinger, L. J. 1993. A structural and functional analysis of the influenza A virus M₂ protein: an ion channel essential for virus entry. Ph.D. dissertation. Northwestern University, Evanston, Ill.
- Holsinger, L. J., and R. A. Lamb. 1991. Influenza virus M₂ integral membrane protein is a homotetramer stabilized by formation of disulfide bonds. *Virology* **183**:32–43.
- Holsinger, L. J., D. Nichani, L. H. Pinto, and R. A. Lamb. 1994. Influenza A virus M₂ ion channel protein: a structure-function analysis. *J. Virol.* **68**:1551–1563.
- Hughey, P. G., R. W. Compans, S. L. Zebedee, and R. A. Lamb. 1992. Expression of the influenza A virus M₂ protein is restricted to apical surfaces of polarized epithelial cells. *J. Virol.* **66**:5542–5552.
- Hull, J. D., R. Gilmore, and R. A. Lamb. 1988. Integration of a small integral membrane protein, M₂, of influenza virus into the endoplasmic reticulum: analysis of the internal signal-anchor domain of a protein with an ectoplasmic NH₂ terminus. *J. Cell Biol.* **106**:1489–1498.
- Jackson, D. C., X. L. Tang, K. G. Murti, R. G. Webster, G. W. Tregear, and W. J. Bean. 1991. Electron microscopic evidence for the association of M₂ protein with the influenza virion. *Arch. Virol.* **118**:199–207.
- Kemp, B. E. 1990. *Peptides and protein phosphorylation.* Uniscience CRC Press, Inc., Boca Raton, Fla.
- Lamb, R. A. 1975. The phosphorylation of Sendai virus proteins by a virus particle-associated protein kinase. *J. Gen. Virol.* **26**:249–263.
- Lamb, R. A., and P. W. Choppin. 1976. Synthesis of influenza virus proteins in infected cells: translation of viral polypeptides, including three P polypeptides, from RNA produced by primary transcription. *Virology* **74**:504–519.
- Lamb, R. A., and P. W. Choppin. 1977. The synthesis of Sendai virus polypeptides in infected cells. III. Phosphorylation of polypeptides. *Virology* **81**:382–397.
- Lamb, R. A., and P. W. Choppin. 1981. Identification of a second protein (M₂) encoded by RNA segment 7 of influenza virus. *Virology* **112**:729–737.
- Lamb, R. A., P. R. Etkind, and P. W. Choppin. 1978. Evidence for a ninth influenza viral polypeptide. *Virology* **91**:60–78.
- Lamb, R. A., L. J. Holsinger, and L. H. Pinto. 1994. The influenza A virus M₂ ion channel protein and its role in the influenza virus life cycle. In E. Wimmer (ed.), *Receptor-mediated virus entry into cells*, in press. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Lamb, R. A., and C.-J. Lai. 1982. Spliced and unspliced messenger RNAs synthesized from cloned influenza virus M DNA in an SV40 vector: expression of the influenza virus membrane protein (M₁). *Virology* **123**:237–256.
- Lamb, R. A., C.-J. Lai, and P. W. Choppin. 1981. Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins. *Proc. Natl. Acad. Sci. USA* **78**:4170–4174.
- Lamb, R. A., B. W. J. Mahy, and P. W. Choppin. 1976. The synthesis of Sendai virus polypeptides in infected cells. *Virology* **69**:116–131.
- Lamb, R. A., S. L. Zebedee, and C. D. Richardson. 1985. Influenza virus M₂ protein is an integral membrane protein expressed on the infected-cell surface. *Cell* **40**:627–633.
- Laskey, R. A., and A. D. Mills. 1975. Quantitative film detection of ³H and ¹⁴C in polyacrylamide gels by fluorography. *Eur. J. Biochem.* **56**:335–341.
- Panayotov, P. P., and R. W. Schlesinger. 1992. Oligomeric organization and strain-specific proteolytic modification of the virion M₂ protein of influenza A H1N1 viruses. *Virology* **186**:352–355.
- Parks, G. D., J. D. Hull, and R. A. Lamb. 1989. Transposition of domains between the M₂ and HN viral membrane proteins results in polypeptides which can adopt more than one membrane orientation. *J. Cell Biol.* **109**:2023–2032.
- Parks, G. D., and R. A. Lamb. 1991. Topology of eukaryotic type II membrane proteins: importance of N-terminal positively charged residues flanking the hydrophobic domain. *Cell* **64**:777–787.
- Paterson, R. G., and R. A. Lamb. 1987. Ability of the hydrophobic fusion related external domain of a paramyxovirus F protein to act as a membrane anchor. *Cell* **48**:441–452.
- Paterson, R. G., and R. A. Lamb. 1990. RNA editing by G-nucleotide insertion in mumps virus P-gene mRNA transcripts. *J. Virol.* **64**:4137–4145.
- Paterson, R. G., and R. A. Lamb. 1993. The molecular biology of influenza viruses and paramyxoviruses, p. 35–73. In A. Davidson and R. M. Elliott (ed.), *Molecular virology: a practical approach.* IRL Oxford University Press, Oxford.
- Pearson, R. B., J. R. Woodgett, P. Cohen, and B. E. Kemp. 1985. Substrate specificity of a multifunctional calmodulin-dependent protein kinase. *J. Biol. Chem.* **260**:14471–14476.
- Pinto, L. H., L. J. Holsinger, and R. A. Lamb. 1992. Influenza virus M₂ protein has ion channel activity. *Cell* **69**:517–528.
- Sanger, F., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. *Proc. Natl. Acad. Sci. USA* **74**:5463–5467.
- Schmidt, M. F. G. 1989. Fatty acylation of proteins. *Biochim. Biophys. Acta* **988**:411–426.
- Sugrue, R. J., G. Bahadur, M. C. Zambon, S. M. Hall, A. R. Douglas, and A. J. Hay. 1990. Specific structural alteration of the influenza haemagglutinin by amantadine. *EMBO J.* **9**:3469–3476.
- Sugrue, R. J., R. B. Belshe, and A. J. Hay. 1990. Palmitoylation of the influenza A virus M₂ protein. *Virology* **179**:51–56.
- Sugrue, R. J., and A. J. Hay. 1991. Structural characteristics of the M₂ protein of the influenza A viruses: evidence that it forms a tetrameric channel. *Virology* **180**:617–624.
- Tosteson, M. T., L. H. Pinto, L. J. Holsinger, and R. A. Lamb. 1994. Recon-

- stitution of the influenza virus M₂ ion channel in lipid bilayers. *J. Membr. Biol.* **142**:117–126.
42. **Veit, M., H. D. Klenk, A. Kendal, and R. Rott.** 1991. The M₂ protein of influenza A virus is acylated. *Virology* **184**:227–234.
43. **Wang, C., R. A. Lamb, and L. H. Pinto.** 1994. Measurement of the influenza virus M₂ ion channel activity in mammalian cells. *Virology* **205**:133–140.
44. **Zebedee, S. L.** 1988. Structure and function analysis of the influenza A virus M₂ protein. Ph.D. dissertation. Northwestern University, Evanston, Ill.
45. **Zebedee, S. L., and R. A. Lamb.** 1988. Influenza A virus M₂ protein: monoclonal antibody restriction of virus growth and detection of M₂ in virions. *J. Virol.* **62**:2762–2772.
46. **Zebedee, S. L., C. D. Richardson, and R. A. Lamb.** 1985. Characterization of the influenza virus M₂ integral membrane protein and expression at the infected-cell surface from cloned cDNA. *J. Virol.* **56**:502–511.